Compare AMRC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | PCRX |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.0B |
| IPO Year | 2010 | 2011 |
| Metric | AMRC | PCRX |
|---|---|---|
| Price | $29.21 | $26.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $33.22 | $32.86 |
| AVG Volume (30 Days) | 483.5K | ★ 761.2K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.87 | N/A |
| EPS | ★ 1.19 | 0.47 |
| Revenue | ★ $1,883,767,000.00 | $716,791,000.00 |
| Revenue This Year | $9.67 | $6.24 |
| Revenue Next Year | $9.89 | $9.53 |
| P/E Ratio | ★ $24.88 | $55.55 |
| Revenue Growth | ★ 12.22 | 3.14 |
| 52 Week Low | $8.49 | $18.17 |
| 52 Week High | $44.93 | $27.64 |
| Indicator | AMRC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.18 | 69.80 |
| Support Level | $28.69 | $25.17 |
| Resistance Level | $36.02 | $27.16 |
| Average True Range (ATR) | 1.51 | 0.98 |
| MACD | -0.34 | 0.25 |
| Stochastic Oscillator | 6.49 | 85.16 |
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.